Jazz Pharmaceuticals Plc - 10-Q Summary (Q2 2009)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2009. Jazz Pharmaceuticals is a specialty pharmaceutical company focused on neurology and psychiatry. Its primary marketed products are Xyrem (sodium oxybate) for narcolepsy and Luvox CR (fluvoxamine maleate) for obsessive compulsive disorder and social anxiety disorder. The company is also developing JZP-6 (sodium oxybate) for fibromyalgia, with a New Drug Application (NDA) planned for submission by the end of 2009.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2009 | Six Months Ended June 30, 2009 |
|---|---|---|
| Total Revenues | $37.3 million | $59.4 million |
| Net Income (Loss) | $2.2 million | $(10.8) million |
| Net Income (Loss) Per Share (Diluted) | $0.07 | $(0.37) |
| Cash and Cash Equivalents | $15.8 million (as of June 30, 2009) | N/A |
| Senior Secured Notes (Principal) | $119.5 million | N/A |
| Accrued Interest (Pre-Payment) | $14.6 million | N/A |
Liquidity: As of June 30, 2009, the company held $15.8 million in cash and cash equivalents. The company had a stockholders' deficit of $88.9 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 140% for the three months ended June 30, 2009, compared to the same period in 2008. This was driven by a 79% increase in product sales (primarily Xyrem due to price increases and volume growth) and a significant increase in contract revenues due to the recognition of a $10.0 million milestone payment from UCB Pharma.
- Profitability: The company reported a net income of $2.2 million for the quarter, a turnaround from a net loss of $51.9 million in the same period in 2008. This improvement was largely due to the milestone revenue and a 60% reduction in Selling, General, and Administrative (SG&A) expenses.
- Expense Reduction: Research and Development (R&D) expenses decreased 49% year-over-year for the quarter, and SG&A expenses decreased 60%, reflecting cost-cutting measures and workforce reductions implemented in 2008.
- Debt Status: The company had defaulted on interest payments totaling $14.6 million due in December 2008, March 2009, and June 2009. This triggered a default rate increase on Senior Notes from 15% to 17%.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The company's independent auditors have raised substantial doubt about its ability to continue as a going concern due to recurring losses and net capital deficiency. Management believes it can fund operations for the next 12 months based on recent cash flows and cost reductions, but this is contingent on revenue assumptions.
- Debt Resolution (Subsequent Event): On July 7, 2009, the company paid the $14.6 million in accrued interest to cure the default on its Senior Notes. Simultaneously, it completed a private placement raising approximately $7.0 million through the sale of common stock and warrants.
- Regulatory Outlook: The company plans to submit an NDA for JZP-6 (fibromyalgia) by the end of 2009. Approval is uncertain and could be delayed or denied.
- Supply Chain Risks: The company relies on sole suppliers for active pharmaceutical ingredients. Delays by Elan Pharma in producing Luvox CR have been noted, which could materially affect the business.
- Unusual Items: The $10.0 million contract revenue recognized in Q2 2009 was a non-recurring milestone payment from UCB Pharma related to the completion of a Phase III clinical trial.
Investor Verification Checklist
- Debt Covenants: Verify the terms of the Senior Notes agreement to ensure the default has been fully cured and that the requirement to maintain restricted cash balances is suspended based on the $100 million annualized net sales test.
- Cash Runway: Assess the sufficiency of the $15.8 million cash balance plus the $7.0 million raised in July 2009 against upcoming debt service obligations and operating expenses.
- JZP-6 Approval Probability: Evaluate the likelihood of FDA approval for JZP-6 given the competitive landscape (Lyrica, Cymbalta, Savella) and the potential need for a Risk Evaluation and Mitigation Strategy (REMS).
- Luvox CR Supply: Confirm the status of manufacturing delays with Elan Pharma and the impact on Luvox CR revenue projections.
- Revenue Sustainability: Analyze whether the Q2 revenue spike (driven by the $10M milestone) is indicative of future performance or a one-time event.